开云app官网登录入口网页版-官方正版

#拜耳#

119篇内容 | 2723人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1318518, encodeId=306c1318518ea, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=在华140年，拜耳继往开来，赴第五年“进博之约”, objectType=article, longId=733543, objectId=54a1e335432c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54a1e335432c, replyNumber=0, likeNumber=59, createdTime=2022-07-29, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54a1e335432c, moduleTitle=在华140年，拜耳继往开来，赴第五年“进博之约”, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=54a1e335432c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318517, encodeId=60c2131851e8c, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=新选择！拜耳非奈利酮在中国获批，用于治疗2型糖尿病相关的慢性肾脏病成人患者, objectType=article, longId=730785, objectId=2df3e30785d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2df3e30785d0, replyNumber=0, likeNumber=86, createdTime=2022-06-30, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2df3e30785d0, moduleTitle=新选择！拜耳非奈利酮在中国获批，用于治疗2型糖尿病相关的慢性肾脏病成人患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=2df3e30785d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318516, encodeId=fa0d1318516a3, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳在欧盟递交非奈利酮用于早期慢性肾病伴2型糖尿病患者的适应症扩展申请, objectType=article, longId=300980, objectId=c76b300980ba, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c76b300980ba, replyNumber=0, likeNumber=74, createdTime=2022-03-18, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c76b300980ba, moduleTitle=拜耳在欧盟递交非奈利酮用于早期慢性肾病伴2型糖尿病患者的适应症扩展申请, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c76b300980ba)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318515, encodeId=786913185156d, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳CKD药物Kerendia获得欧盟批准, objectType=article, longId=299786, objectId=c72e299e86e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c72e299e86e4, replyNumber=0, likeNumber=78, createdTime=2022-03-02, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c72e299e86e4, moduleTitle=拜耳CKD药物Kerendia获得欧盟批准, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=c72e299e86e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318514, encodeId=557e131851427, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳XIa因子抑制剂的卒中临床项目获得美国 FDA 快速通道认证, objectType=article, longId=298997, objectId=67d929899e31, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=67d929899e31, replyNumber=0, likeNumber=87, createdTime=2022-02-19, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=67d929899e31, moduleTitle=拜耳XIa因子抑制剂的卒中临床项目获得美国 FDA 快速通道认证, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=67d929899e31)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318513, encodeId=356e13185132a, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳放弃研发P2X3受体拮抗剂eliapixant, objectType=article, longId=295169, objectId=7fe7295169ea, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fe7295169ea, replyNumber=0, likeNumber=98, createdTime=2022-02-07, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fe7295169ea, moduleTitle=拜耳放弃研发P2X3受体拮抗剂eliapixant, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=7fe7295169ea)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318511, encodeId=4e2e131851133, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=缓解慢性肾病进展还能降低心血管风险，拜耳新药Kerendia 或拥有巨大潜力, objectType=article, longId=215492, objectId=aa4d21549233, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa4d21549233, replyNumber=0, likeNumber=83, createdTime=2021-08-11, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa4d21549233, moduleTitle=缓解慢性肾病进展还能降低心血管风险，拜耳新药Kerendia 或拥有巨大潜力, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aa4d21549233)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318510, encodeId=21e71318510ab, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳将以20亿美元收购小分子新药发现平台Vividion，加强制药板块雄心, objectType=article, longId=215380, objectId=18142153803d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18142153803d, replyNumber=0, likeNumber=72, createdTime=2021-08-07, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18142153803d, moduleTitle=拜耳将以20亿美元收购小分子新药发现平台Vividion，加强制药板块雄心, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=18142153803d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318512, encodeId=c7fe131851240, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳启动Elinzanetant III期临床研发项目OASIS，用于治疗更年期血管舒缩症状, objectType=article, longId=214643, objectId=e3b121464360, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e3b121464360, replyNumber=0, likeNumber=76, createdTime=2021-07-24, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e3b121464360, moduleTitle=拜耳启动Elinzanetant III期临床研发项目OASIS，用于治疗更年期血管舒缩症状, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=e3b121464360)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318508, encodeId=f86b13185086d, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=糖尿病肾病新药！拜耳首创药物非奈利酮显著降低房颤发生风险, objectType=article, longId=211414, objectId=247f2114145e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=247f2114145e, replyNumber=0, likeNumber=81, createdTime=2021-05-18, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=247f2114145e, moduleTitle=糖尿病肾病新药！拜耳首创药物非奈利酮显著降低房颤发生风险, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=247f2114145e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318507, encodeId=5ac8131850e98, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点, objectType=article, longId=210971, objectId=aae42109e1a9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aae42109e1a9, replyNumber=0, likeNumber=75, createdTime=2021-05-10, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aae42109e1a9, moduleTitle=III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=aae42109e1a9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318509, encodeId=31091318509ba, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳全新症状性慢性心衰治疗药物维立西呱在欧盟获批, objectType=article, longId=209867, objectId=cdf020986e23, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdf020986e23, replyNumber=0, likeNumber=65, createdTime=2021-04-14, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdf020986e23, moduleTitle=拜耳全新症状性慢性心衰治疗药物维立西呱在欧盟获批, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cdf020986e23)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318506, encodeId=1d8513185064b, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳去年净亏损约105亿欧元，销售榜首利伐沙班面临专利悬崖, objectType=article, longId=208154, objectId=66cc208154dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66cc208154dd, replyNumber=0, likeNumber=56, createdTime=2021-03-09, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66cc208154dd, moduleTitle=拜耳去年净亏损约105亿欧元，销售榜首利伐沙班面临专利悬崖, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=66cc208154dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318505, encodeId=3d8313185057b, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳，ViiV和RB等药企采用创新的思维，挑战药品营销创造力的极限, objectType=article, longId=202958, objectId=d2b2202958d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2b2202958d0, replyNumber=0, likeNumber=85, createdTime=2020-11-07, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2b2202958d0, moduleTitle=拜耳，ViiV和RB等药企采用创新的思维，挑战药品营销创造力的极限, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d2b2202958d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318504, encodeId=a2f91318504d9, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, objectType=article, longId=202599, objectId=ad7320259999, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ad7320259999, replyNumber=0, likeNumber=81, createdTime=2020-10-30, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ad7320259999, moduleTitle= 拜耳Finerenone FIDELIO-DKD III期临床研究结果公布, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=ad7320259999)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318503, encodeId=6b39131850379, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳的Nubeqa获得NICE支持，用于治疗前列腺癌, objectType=article, longId=202563, objectId=5a2620256367, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5a2620256367, replyNumber=0, likeNumber=70, createdTime=2020-10-29, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5a2620256367, moduleTitle=拜耳的Nubeqa获得NICE支持，用于治疗前列腺癌, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=5a2620256367)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318502, encodeId=11a7131850264, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳斥资40亿美元收购基因治疗公司AskBio, objectType=article, longId=202541, objectId=4ccf20254192, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4ccf20254192, replyNumber=0, likeNumber=87, createdTime=2020-10-28, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4ccf20254192, moduleTitle=拜耳斥资40亿美元收购基因治疗公司AskBio, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=4ccf20254192)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318501, encodeId=243813185013b, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……, objectType=article, longId=200934, objectId=8f8c200934f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8c200934f5, replyNumber=0, likeNumber=65, createdTime=2020-09-21, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8c200934f5, moduleTitle=吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8f8c200934f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318500, encodeId=f7a9131850001, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳以2.5亿欧元收购印度公司Curadev的STING抑制剂，用于治疗炎症性疾病, objectType=article, longId=190888, objectId=77241908883c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=77241908883c, replyNumber=0, likeNumber=81, createdTime=2020-03-28, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=77241908883c, moduleTitle=拜耳以2.5亿欧元收购印度公司Curadev的STING抑制剂，用于治疗炎症性疾病, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=77241908883c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318499, encodeId=a4bb131849947, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳的Eylea在针对湿性年龄相关性黄斑变性的ALTAIR IV期研究中展现出疗效和安全性, objectType=article, longId=187857, objectId=d62e18e85710, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d62e18e85710, replyNumber=0, likeNumber=80, createdTime=2020-02-13, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d62e18e85710, moduleTitle=拜耳的Eylea在针对湿性年龄相关性黄斑变性的ALTAIR IV期研究中展现出疗效和安全性, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d62e18e85710)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

拜耳

2020-05-29

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

在华140年，拜耳继往开来，赴第五年“进博之约”

2022-07-29

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

新选择！拜耳非奈利酮在中国获批，用于治疗2型糖尿病相关的慢性肾脏病成人患者

2022-06-30

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳在欧盟递交非奈利酮用于早期慢性肾病伴2型糖尿病患者的适应症扩展申请

2022-03-18

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳CKD药物Kerendia获得欧盟批准

2022-03-02

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳XIa因子抑制剂的卒中临床项目获得美国 FDA 快速通道认证

2022-02-19

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳放弃研发P2X3受体拮抗剂eliapixant

2022-02-07

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

缓解慢性肾病进展还能降低心血管风险，拜耳新药Kerendia 或拥有巨大潜力

2021-08-11

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳将以20亿美元收购小分子新药发现平台Vividion，加强制药板块雄心

2021-08-07

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳启动Elinzanetant III期临床研发项目OASIS，用于治疗更年期血管舒缩症状

2021-07-24

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

糖尿病肾病新药！拜耳首创药物非奈利酮显著降低房颤发生风险

2021-05-18

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

III期临床FIGARO-DKD研究结果：拜耳非奈利酮在慢性肾病合并2型糖尿病患者中达到心血管首要复合终点

2021-05-10

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳全新症状性慢性心衰治疗药物维立西呱在欧盟获批

2021-04-14

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳去年净亏损约105亿欧元，销售榜首利伐沙班面临专利悬崖

2021-03-09

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳，ViiV和RB等药企采用创新的思维，挑战药品营销创造力的极限

2020-11-07

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳Finerenone FIDELIO-DKD III期临床研究结果公布

2020-10-30

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳的Nubeqa获得NICE支持，用于治疗前列腺癌

2020-10-29

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳斥资40亿美元收购基因治疗公司AskBio

2020-10-28

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

吉利德Kite副总裁离职、拜耳CEO任期延长、BMS肿瘤研发首脑加入Blueprint……

2020-09-21

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳以2.5亿欧元收购印度公司Curadev的STING抑制剂，用于治疗炎症性疾病

2020-03-28

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳的Eylea在针对湿性年龄相关性黄斑变性的ALTAIR IV期研究中展现出疗效和安全性

2020-02-13

科室
- - 订阅+
  - 更多科室
工具
服务